Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.

Date publication

avril 2025

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc

Tous les auteurs :
Penel N, Italiano A, Wallet J, Chaigneau L, Verret B, Firmin N, Watson S, Valentin T, Bompas E, Bertucci F, Brahmi M, Henon C, Brunot A, Spalato-Ceruso M, Vanseymortier M, Heyman-Decoupigny E, Ryckewaert T, LE Deley MC, Perrin C, Blay JY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40210087

Résumé

There is no approved maintenance therapy in advanced non-adipocytic soft tissue sarcomas (NASTS). We explore here the role of regorafenib as a potential maintenance therapy after first line treatment.

Mots clés

Maintenance therapy, Placebo-controlled trial, Randomised trial, Regorafenib, Soft tissue sarcomas

Référence

Ann Oncol. 2025 04 8;: